"3·15" Exposes Medical Aesthetics Exosome "Certificate Fraud" Trap, Jinbo Biotechnology Responds

Investing in stocks? Rely on JinQilin Analyst Reports—authoritative, professional, timely, comprehensive—helping you uncover potential thematic opportunities!

Source: Beizheng Information

On March 16, Jinbo Biotech (920982) issued a stern statement regarding the exposure of medical aesthetic exosome chaos at the “3.15” Gala, clarifying industry misconceptions, defining compliance standards, and issuing risk warnings to consumers and practitioners.

According to the “3.15” Gala broadcast by CCTV, the products “Qingcheng” produced by XXX Biotechnology Co., Ltd. were confirmed to illegally use a human-derived collagen type II medical device license and add exosome components without approval. Jinbo Biotech stated that such “license-faking” behavior not only severely violates the “Medical Device Supervision and Administration Regulations,” but also involves injecting unverified substances directly into the human body, risking consumer health. Moreover, this malicious imitation of legitimate product registration certificates seriously disrupts market order and damages the reputation of compliant human-derived collagen companies.

Jinbo Biotech expressed firm support for the National Medical Products Administration’s efforts to crack down on such illegal activities, uphold the safety bottom line of the medical aesthetic market, and maintain zero tolerance for illegal “license-faking” behaviors.

In the statement, Jinbo Biotech explained the regulatory requirements for medical devices, clarifying the red line for compliance in injectable products. According to the “Medical Device Supervision and Administration Regulations,” medical devices injected into human dermis or bloodstream are classified as high-risk Class III devices, which must undergo rigorous pharmaceutical research, clinical trials, and review before obtaining the “Medical Device Registration Certificate (Class III)” for market approval. Conversely, Class II medical devices are only suitable for non-invasive or superficial use and are strictly prohibited from injection. Jinbo Biotech revealed that currently, no exosome-based drugs have been approved for market listing in China, nor has any exosome medical device product been approved for sale. All products claiming to be injectable exosomes on the market are illegal, with unrecognized safety and efficacy—consumers should stay alert.

Additionally, Jinbo Biotech disclosed its compliance credentials: it is currently the only domestic company holding three Class III medical device registration certificates mainly for “human-derived collagen” products, approved by the National Medical Products Administration, with registration numbers: GuoXieZhun20213130488, GuoXieZhun20233131245, and GuoXieZhun20253130751. The company stated that these certificates are the result of long-term scientific research, strict clinical validation, and standardized production, serving as the core basis for product compliance and safety.

For consumers and medical aesthetic practitioners, Jinbo Biotech reminds to recognize legal boundaries: injectable products must have a valid Class III medical device registration certificate; beware of “license-faking” tricks—carefully verify product name, ingredients, and scope of application to avoid being misled by unscrupulous vendors; before injection, you can check the National Medical Products Administration’s official website to verify registration certificate numbers and scope, ensuring the products used are legal and compliant.

Jinbo Biotech’s main business involves the research, production, and sales of various medical devices and functional skincare products centered on recombinant collagen and anti-HPV bio-proteins. On June 29, 2021, its self-developed Class III medical device “Recombinant Type III Human-Derived Collagen Lyophilized Fiber” was approved for market listing by the National Medical Products Administration. This product is China’s first medical device made from a new biological material—recombinant human-derived collagen—laying a solid foundation for clinical application and industrial transformation of related materials.

On July 20, 2023, Jinbo Biotech listed on the Beijing Stock Exchange, becoming the “First Reconstructed Collagen Stock” on the BSE. As of the close on March 16, the company’s market value was 20.942 billion yuan, ranking third on the BSE.